Search

Your search keyword '"McNeish, Iain A."' showing total 941 results

Search Constraints

Start Over You searched for: Author "McNeish, Iain A." Remove constraint Author: "McNeish, Iain A."
941 results on '"McNeish, Iain A."'

Search Results

1. Integrative multi-omics analyses to identify the genetic and functional mechanisms underlying ovarian cancer risk regions.

2. Genome-wide association analyses of ovarian cancer patients undergoing primary debulking surgery identify candidate genes for residual disease

3. BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance

4. Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer

6. Homologous recombination deficiency in ovarian cancer: Global expert consensus on testing and a comparison of companion diagnostics

7. How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomes

8. Interferon-ε is a tumour suppressor and restricts ovarian cancer

9. Molecular landscape and functional characterization of centrosome amplification in ovarian cancer

10. Author Correction: The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma

11. The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma

12. Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2

13. Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2).

15. Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis

17. Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE)

18. Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors

19. Homologous recombination deficiency in newly diagnosed FIGO stage III/IV high-grade epithelial ovarian cancer: a multi-national observational study

22. Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup

23. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial

24. Homologous recombination deficiency testing in patients with high grade ovarian cancer: factors influencing test success.

25. Enhancing oncolytic virotherapy by extracellular vesicle mediated microRNA reprograming of the tumour microenvironment.

26. Polygenic risk modeling for prediction of epithelial ovarian cancer risk

27. Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk

28. A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk

29. rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology.

30. Clonal somatic copy number altered driver events inform drug sensitivity in high-grade serous ovarian cancer

31. Enhancing oncolytic virotherapy by exosome-mediated microRNA reprograming of the tumour microenvironment.

32. Phase II randomized multi-centre study of neoadjuvant olaparib in patients with platinum sensitive relapsed high grade serous ovarian cancer: The NEO trial.

33. ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA–MONO) and rucaparib in combination with nivolumab (ATHENA–COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer

34. Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer

37. Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility

38. Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING

40. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

41. Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium

42. No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival

44. Objective responses to first-line neoadjuvant carboplatin–paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial

46. The Hammersmith Score Optimises Patient Selection and Predicts for Overall Survival in Early-Phase Cancer Trial Participants Independent of Tumour Burden.

47. The genomic trajectory of ovarian high‐grade serous carcinoma can be observed in STIC lesions.

49. Evaluation of surgical resection in advanced ovarian, fallopian tube, and primary peritoneal cancer: laparoscopic assessment. A European Network of Gynaecological Oncology Trial (ENGOT) group survey

Catalog

Books, media, physical & digital resources